Schizophrenia in Pregnancy

doi:10.1017/9781108975780.036

Chapter 30 - Schizophrenia in Pregnancy

from Section 5 - Psychiatric Disorders in Pregnancy

Published online by Cambridge University Press: 23 February 2023

Amira El-Messidi and

Nicolas Beaulieu

Edited by

Amira El-Messidi and

Alan D. Cameron

Show author details

Amira El-Messidi: Affiliation:
McGill University, Montréal
Alan D. Cameron: Affiliation:
University of Glasgow

Book contents

Get access

Summary

A 30-year-old primigravida with schizophrenia is referred by her primary care provider to your high-risk obstetrics unit at a tertiary center. Her mental illness is controlled by clozapine, and she takes routine prenatal vitamins. The patient is at 12+2 weeks’ gestation by dating sonography; first-trimester fetal anatomy was normal with a low risk of aneuploidy. Results of routine prenatal investigations are unremarkable. The patient does not have any obstetric complaints.

Keywords

Schizophrenia, pregnancy Antipsychotics Investigations Clozapine, maternal and fetal risks Antenatal management Acute psychosis Informed consent Postpartum care

Type: Chapter
Information: OSCEs in Obstetrics and Maternal-Fetal Medicine
An Evidence-Based Approach
, pp. 397 - 406

DOI: https://doi.org/10.1017/9781108975780.036 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2023

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Suggested Readings

ACOG Committee on Practice Bulletins – Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists No. 92. Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008;111(4):1001–1020.Google Scholar

Appelbaum, PS. Clinical practice: assessment of patients’ competence to consent to treatment. N Engl J Med. 2007;357(18):1834–1840.Google Scholar

Birnbaum, R, Weinberger, DR. Pharmacological implications of emerging schizophrenia genetics: can the bridge from ‘genomics’ to ‘therapeutics’ be defined and traversed? J Clin Psychopharmacol. 2020;40(4):323–329.CrossRef Google Scholar

Breadon, C, Kulkarni, J. An update on medication management of women with schizophrenia in pregnancy. Expert Opin Pharmacother. 2019;20(11):1365–1376.Google Scholar

Chisolm, MS, Payne, JL. Management of psychotropic drugs during pregnancy. BMJ. 2016;532:h5918.Google Scholar

Hasan, A, Falkai, P, Wobrock, T, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of schizophrenia. Part 3: Update 2015 Management of special circumstances: Depression, suicidality, substance use disorders and pregnancy and lactation. World J Biol Psychiatry. 2015;16(3):142–170.CrossRef Google Scholar PubMed

Jones, I, Chandra, PS, Dazzan, P, et al. Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period. The Lancet. 2014 Nov 15;384(9956):1789–1799.Google Scholar

Poo, SX, Agius, M. Atypical antipsychotics for schizophrenia and/or bipolar disorder in pregnancy: current recommendations and updates in the NICE guidelines. Psychiatr Danub. 2015;27(Suppl 1):S255–S260.Google Scholar

Rasic, D, Hajek, T, Alda, M, et al. Risk of mental illness in offspring of parents with schizophrenia, bipolar disorder, and major depressive disorder: a meta-analysis of family high-risk studies. Schizophr Bull. 2014;40(1):28–38.CrossRef Google Scholar PubMed

Robinson, GE. Treatment of schizophrenia in pregnancy and postpartum. J Popul Ther Clin Pharmacol. 2012;19(3):e380–e386.Google Scholar